Recombinant tumor specific antibody and use thereof
AssigneeMerck Patent GmbH
InventorsStephen D. Gillies, Kin-Ming Lo, Susan Xiuqi Qian
Life of this patent
Estimating the term…
Abstract
The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.
Claims16
An anti-EpCAM protein comprising an antibody that binds human EpCAM, said antibody comprising an immunoglobulin light chain variable region comprising (i) amino acid residues 24-31 of SEQ ID NO:1;
- (ii) amino acid residues 49-55 of SEQ ID NO:1;
- and (iii) amino acid residues 88-96 of SEQ ID NO:1;
- and further comprising an amino acid sequence defining an immunoglobulin light chain framework region selected from the group consisting of:
- (i) amino acid residues 1-23 of SEQ ID NO:8;
- and (ii) amino acid residues 1-23 of SEQ ID NO:9.
An anti-EpCAM protein, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin heavy chain variable region comprising (i) amino acid residues 26-35 of SEQ ID NO:2;
- (ii) amino acid residues 50-62 of SEQ ID NO:2;
- and (iii) amino acid residues 101-105 of SEQ ID NO:2;
- and further comprising an amino acid sequence defining an immunoglobulin heavy chain framework region selected from the group consisting of:
- (i) amino acid residues 1-25 of SEQ ID NO:18;
- and (ii) amino acid residues 67-98 of SEQ ID NO:18.
An anti-EpCAM protein, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an antibody light chain comprising the amino acid sequence defined by residues 1-106 of SEQ ID NO:9 and an antibody heavy chain comprising the amino acid sequence defined by residues 1-116 of SEQ ID NO:18.
A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin light chain variable region comprising (i) amino acid residues 24-31 of SEQ ID NO:1;
- (ii) amino acid residues 49-55 of SEQ ID NO:1;
- and (iii) amino acid residues 88-96 of SEQ ID NO:1;
- and further comprising an amino acid sequence defining an immunoglobulin light chain framework region selected from the group consisting of:
- (i) amino acid residues 1-23 of SEQ ID NO:8;
- and (ii) amino acid residues 1-23 of SEQ ID NO:9.
A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an immunoglobulin heavy chain variable region comprising (i) amino acid residues 26-35 of SEQ ID NO:2;
- (ii) amino acid residues 50-62 of SEQ ID NO:2;
- and (iii) amino acid residues 101-105 of SEQ ID NO:2;
- and further comprising an amino acid sequence defining an immunoglobulin heavy chain framework region selected from the group consisting of:
- (i) amino acid residues 1-25 of SEQ ID NO:18;
- and (ii) amino acid residues 67-98 of SEQ ID NO:18.
A humanized or deimmunized anti-EpCAM protein suitable for administering into a human patient for treating a disease associated with EpCAM over-expression, wherein the protein comprises an antibody that binds human EpCAM, said antibody comprising an antibody light chain comprising the amino acid sequence defined by residues 1-106 of SEQ ID NO:9 and an antibody heavy chain comprising the amino acid sequence defined by residues 1-116 of SEQ ID NO:18.
Dependencies are inferred from the claim text.